| Top Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Legal > Personal Injury > Permax Heart Valve Damage |
|
Top Articles - Permax Heart Valve Damage
Evidence of Permax heart valve damage has increased following a new study published in the March 2007 issue of the medical journal Arc According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product hives of Neurology. This study provides further support of the problems linked to Permax. Heart valve damage was found to increase wit ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in long-term use of the drug. The purpose of this study was to compare Permax patients with those treated with the drugs Mirapex and Req lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. ip. The Federal Drug Administration (FDA) first became aware of Permax heart valve injury problems in 2002. Permax (peroglide) has be here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe en on the market since 1989. Permax has been prescribed to treat Parkinson's patients and people suffering from Restless Legs Syndrome d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro A black box warning was added to the drug's label in 2006 as a result of increasing concern over Permax heart valve damage side effec ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc s. Recent studies were conducted in Britain and Italy to evaluate serious concerns that Permax heart valve damage occurred with long- easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi term use of the drug. In the British study, 11,417 people were given Permax. The test subjects were 37 times more likely to develop he nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically rt problems. The Italian study involved 155 Parkinson's patients who were taking Permax. Heart valve damage was reported in 23.4% of t and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ e people taking the drug in that study. The Mayo Clinic has also reported problems with Permax heart valve injury. According to a rep ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi rt by doctors at the Mayo Clinic, three patients who took Permax for three to seven years suffered serious heart valve damage. Two of ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a the patients had significant heart damage requiring valve replacement surgery. The Mayo Clinic doctors recommended that given the dang dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod rs associated with Permax, patients with heart problems should not take the drug. Permax heart valve damage symptoms include chest pa cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin n, shortness of breath and swelling of the feet and ankles. In some cases, patients with serious heart valve injuries can require hear tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen t valve replacement or if left untreated, the patient may suffer heart failure resulting in death. Heart valve damage inhibits valves t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel from opening or closing. There are two primary types of heart valve disease. Stenosis (obstruction) occurs when a valve opening become ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust narrowed, making it difficult do pump blood throughout the body. Regurgitation (insufficiency) is when a valve is prevented from comp y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products letely closing causing the blood to leak backward instead of flowing forward. On March 29, 2007, following the increasing evidence of . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de Permax heart valve damage problems, the FDA announced a Permax recall. In light of the recall, the FDA is prompting patients currently elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip taking the drug to discuss alternative treatment options with their doctor and monitor for possible Permax heart valve injury problems tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Focusing On Niche Marketing Brings You More Beyond the Box with Google's Web API
|